The latest in z.ai's ongoing and continually impressive GLM series, it retains an open source MIT License — perfect for enterprise deployment – and, in one of several notable achievements, achieves a ...
When most people think about special forces gear, the focus usually lands on suppressed weapons, night vision devices, and the visible tools of direct action. In reality, many of the technologies that ...
The OpenFit Air feature a lightweight, open-ear design that allows you to remain aware of your surroundings. They’re ...
No two special operations missions unfold the same way, and the difference between success and failure often hinges on how quickly a team can adapt. For U.S. Navy SEALs flexibility is built directly ...
Researchers uncover SSHStalker, an IRC botnet exploiting legacy Linux flaws and SSH servers to build persistent covert access.
At CES 2026, GIGABYTE is unlocking the full potential of AMD Ryzen™ 9000 Series Processors with AMD 3D V-Cache technology. Through its exclusive, AI-powered X3D Turbo Mode 2.0, GIGABYTE delivers ...
Posts from this topic will be added to your daily email digest and your homepage feed. MSI’s new part-gaming laptop, part-creator laptop comes with Intel Panther Lake and Nvidia GPUs. MSI’s new ...
Once living room eyesores, the functional chairs have been revamped. The Grady Notch recliner from the interiors brand Serena & Lily is designed to blend in with other furniture. Credit...Serena and ...
Flashy wealth is out. Quiet wealth is in. In 2025, it's not the person posting luxury vacations on Instagram who's winning; it's the one with a paid-off mortgage and maxed-out retirement accounts. The ...
After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy ...
After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational treatment designed to treat an ultra-rare genetic disease. This is the biotech’s ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results